The Microbiome & Allergic Disease
According to the Centers for Disease Control and Prevention, chronic illnesses are now the leading cause of morbidity and mortality in the United States. This includes chronic inflammatory diseases of the airway such as asthma and allergies, which are also on the rise globally. Asthma affects over 330 million people worldwide, and an estimated 60-70% of asthmatics in the US suffer from allergic asthma. Allergic asthma is characterized by hypersensitivity, and shares the same underlying immune system dysfunction with other atopic diseases such as rhinitis and eczema. For example, these allergic diseases share characteristic type 2 helper T cell activation and IgE antibody generation toward benign environmental antigens. Current standard of care treatments such as antihistamines, steroids, bronchodilators and biologics, target the downstream inflammation that results from this inappropriate immune response. Additionally, these current standards of care provide variable efficacy and can result in significant side effects.
The gut microbiome affects the health of the entire body
Strong evidence supports the role of the early-life infant gut microbiome in establishing proper immune function. With this in mind, early-life disruptions to gut microbiome development are associated with an increased risk of allergy and asthma. Building on our growing understanding, and a combination of decades of microbiome research experience, we have developed a systems-based platform that delivers patient screening and stratification, immunomodulatory validation, and targeted microbial therapeutics for the treatment of inflammatory diseases. Using this strategy, we have developed our lead therapeutic for the prevention and treatment of allergic asthma. Siolta’s preclinical proof of concept studies show that our lead mixed-species microbial therapeutic protects against allergic airway inflammation. In contrast to currently available therapies, Siolta Therapeutic’s microbiome-based approach towards allergic asthma aims to prevent the initiation of the immune dysfunction cascade, thus preventing allergic disease before it starts.
Asthma and Microbiome Resources
|NIH Human Microbiome Project||NOVA Microbiome||What’s Living In You?|
|Can You Change Your Microbiome?||NPR: Probiotics For Babies And Kids?|